• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Gland Pharma Ltd.
    04 Jun 2025
    Insider Trades
    1991.60
    -0.32%
    USFDA clears Gland Pharma's generic Angiotensin II injection
    Business Line
    The drug is used to raise blood pressure in adults with septic or other distributive shock.
    Copy LinkShare onShare on Share on Share on
    Gland Pharma Ltd. is trading above all available SMAs
    Gland Pharma share rises 2% in trade on Wednesday, June 4; here's why
    Business Standard | 04 Jun 2025
    logo
    Sun Pharmaceutical Industries Ltd.
    04 Jun 2025
    1594.30
    0.31%
    Modest setback for Sun Pharma, 18% fall in SPARC shares as drug fails to deliver
    Business Line
    SPARC, the R&D arm of Sun Pharma, was testing SCD-044 for two auto-immune indications in a Phase-2 trial. Though the study did not show any safety concerns, the drug failed the endpoint of a 75 per cent improvement in PASI score and EASI score at week 16
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
    Sun Pharma Advanced Research shares tank 20% after psoriasis drug fails Phase 2 trials
    Economic Times | 04 Jun 2025 4 more
    Sun Pharma Advanced Research Shares Fall To Nearly One-Month Low On Discontinuing Psoriasis Drug
    NDTV Profit | 04 Jun 2025
    Sun Pharma Advanced Research shares fell 15%; What's rattling investors?
    Business Standard | 04 Jun 2025
    Sun Pharma discontinues 2 trials of drug candidate for not meeting primary endpoints
    Business Line | 03 Jun 2025
    Sun Pharma halts development of SCD-044 drug after trial disappointment
    Business Standard | 03 Jun 2025
    logo
    Sun Pharma Advanced Research Company Ltd.
    04 Jun 2025
    129.52
    0.57%
    SPARC shares fall 18% as drug candidate gets discontinued
    Business Line
    At 12.26 pm on Wednesday, SPARC shares were at down -18.25 per cent at 159.90
    Copy LinkShare onShare on Share on Share on
    Sun Pharma Advanced Research Company Ltd. has lost -39.04% in the last 1 Year
    logo
    Wockhardt Ltd.
    04 Jun 2025
    1516.00
    -3.09%
    Wockhardt Aims To Regain Rs 5,000-Crore Revenue In Three Years, Says Chairperson Khorakiwala
    Wockhardt Aims To Regain Rs 5,000-Crore Revenue In Three Years, Says Chairperson Khorakiwala
    NDTV Profit
    In FY25, the company's revenue stood at Rs 3,012 crore, compared to Rs 2,798 crore in FY24.
    Copy LinkShare onShare on Share on Share on
    Wockhardt Ltd. has gained 53.78% in the last 1 Year
    logo
    Alkem Laboratories Ltd.
    03 Jun 2025
    5425.00
    0.30%
    Alkem Promoter Jayanti Sinha To Sell 1.42% Stake Via Block Deal
    Alkem Promoter Jayanti Sinha To Sell 1.42% Stake Via Block Deal
    NDTV Profit
    The floor price for the shares has been set at Rs 4,850 apiece, a discount of about 3% to Alkem's current market price.
    Copy LinkShare onShare on Share on Share on
    Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.
    logo
    Indoco Remedies Ltd.
    03 Jun 2025
    291.95
    0.69%
    Indoco Remedies Subsidiary Launches Generic Drug In UK
    Indoco Remedies Subsidiary Launches Generic Drug In UK
    NDTV Profit
    This significant addition to Indo Remedies portfolio will be marketed and distributed by Clarity Pharma across the UK, it added.
    Copy LinkShare onShare on Share on Share on
    Indoco Remedies Ltd. is trading below its 50 day SMA of 294.0
    logo
    Dr. Reddy's Laboratories Ltd.
    02 Jun 2025
    1223.70
    -0.88%
    A test case' unfolds over Novo Nordisk's weight loss and diabetes drug semaglutide
    Business Line
    Novo Nordisk is locked in a patent infringement battle with Dr Reddy's Laboratories and OneSource Specialty Pharma
    Copy LinkShare onShare on Share on Share on
    Deven Choksey released a Sell report for Dr. Reddy's Laboratories Ltd. with a price target of 1120.0 on 11 Sep, 2025.
    logo
    AstraZeneca Pharma India Ltd.
    02 Jun 2025
    9105.50
    2.41%
    AstraZeneca Pharma shares surge 12% after Q4 results; profit jumps 48%
    Business Standard
    AstraZeneca Pharma India rallied nearly 12 per cent after its net profit for the fourth quarter of the previous financial year jumped 48 per cent
    Copy LinkShare onShare on Share on Share on
    AstraZeneca Pharma India Ltd.'s price crossed above 100Day SMA today
    AstraZeneca Pharma India Share Price Jumps Post Q4 Profit, Margin Growth
    NDTV Profit | 02 Jun 2025
    logo
    Sun Pharmaceutical Industries Ltd.
    02 Jun 2025
    1594.30
    0.31%
    New launches to drive Sun Pharma's future growth; PAT may take a hit by tax surge
    New launches to drive Sun Pharma's future growth; PAT may take a hit by tax surge
    Economic Times
    Sun Pharma anticipates revenue growth for fiscal year 26, building on an 8% increase in fiscal year 25. However, increased spending on marketing specialty products may impact profitability. Net profit declined in the March quarter due to higher taxes. The company plans to launch new drugs like Leqselvi and Unloxcyt.
    Copy LinkShare onShare on Share on Share on
    Motilal Oswal released a Buy report for Sun Pharmaceutical Industries Ltd. with a price target of 1960.0 on 23 Sep, 2025.
    Sun Pharma Lines Up $100 Million To Commercialise Niche Products This Fiscal
    NDTV Profit | 01 Jun 2025 2 more
    Sun Pharma to invest $100 mn in commercialising speciality products this fiscal
    Business Line | 01 Jun 2025
    Sun Pharma lines up $100 mn to commercialise niche products in FY26
    Business Standard | 01 Jun 2025
    logo
    Ipca Laboratories Ltd.
    01 Jun 2025
    1339.00
    1.67%
    Ipca Labs Q4 Results Review: Dolat Capital Maintains 'Add', Revises Target Price
    Ipca Labs Q4 Results Review: Dolat Capital Maintains 'Add', Revises Target Price
    NDTV Profit
    Dolat Capital maintains Accumulate' rating at 30x FY27E P/E with a revised target price of Rs 1,604.
    Copy LinkShare onShare on Share on Share on
    Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • Rukmani Devi Garg Agro Impex
    • KVS Castings
    • Om Freight Forwarders
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd (RA SEBI Reg No: INH000022507)